In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors

British Journal of Pharmacology

Volumn 121, Issue 2, 1997, Pages 221-231

  Gantner, Florian ^a   Kupferschmidt, Rochus ^a   Schudt, Christian ^a   Wendel, Albrecht ^a   Hatzelmann, Armin ^a,b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

Cyclic AMP; LPS; Monocyte derived macrophages; PDE inhibitors; PDE isoenzymes; Prostaglandin E2; Tumour necrosis factor

Indexed keywords

ACID PHOSPHATASE; BUCLADESINE; CD14 ANTIGEN; CYCLIC AMP; DEXAMETHASONE; ESTERASE; FORSKOLIN; LIPOPOLYSACCHARIDE; MOTAPIZONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PICLAMILAST; PROSTAGLANDIN E2; ROLIPRAM; TOLAFENTRINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZAPRINAST;

ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030997247     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701124     Document Type: Article

References (92)

1. ARAI, T., HIROMATSU, K., KOBAYASHI, N., TAKANO, M., ISHIDA, H., NIMURA, Y. & YOSHIKAI, Y. (1995). IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J. Immunol., 155, 5743-5749.
2. BANNER, K.H., ROBERTS, N. & PAGE, C. (1995). Differential effects of phosphodiesterase IV inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br. J. Pharmacol., 116, 3169-3174.
3. BAUER, A.C. & SCHWABE, U. (1980). An improved assay of cyclic 3′, 5′-nucleotide phosphodiesterase with QAE Sephadex A-25. Naunyn-Schmiedeberg's Arch. Pharmacol., 311, 193-198.
4. BAUER, J., GANTER, U., GEIGER, T., JACOBSHAGEN, U., HIRANO, T., MATSUDA, T., KISHIMOTO, T., ANDUS, T., ACS, G., GEROK, W. & CILIBERTO, G. (1988). Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages. Blood, 72, 1134-1140.
5. BEAVO, J.A., CONTI, M. & HEASLIP, R.J. (1994). Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 46, 399-405.
6. BECKER, S., WARREN, M.K. & HASKILL, S. (1987). Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J. Immunol., 139, 3703-3709.
7. BEUTLER, B. & CERAMI, A. (1988). Tumor necrosis, cachexia shock, and inflammation: a common mediator. Annu. Rev. Biochem., 57, 505-518.
8. BOLGER, G.B. (1994). Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signalling, 6, 851-859.
9. BROIDE, D.H., LOTZ, M., CUOMON, A.J., COBURN, D.A., FEDERMAN, E.C. & WASERMAN, S.I. (1992). Cytokines in symptomatic asthma. J. Allergy Clin. Immunol., 89, 958-967.
10. BURCHETT, S.K., WEAVER, W.M., WESTHALL, J.A., LARSEN, A., KRONHEIM, S. & WILSON, C.B. (1988). Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J. Immunol., 140, 3473-3481.
11. BURTON, K. (1956). A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J., 62, 315-323.
12. CEMBRZYNSKY-NOWAK, M., SZEKLARZ, E., INGLOT, A.D. & TEODORCZYK-INJEYAN, J.A. (1993). Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am. Rev. Respir. Dis., 147, 291-295.
13. DENT, G. & GIEMBYCZ, M.A. (1996). Interaction of PDE4 inhibitors with enzymes and cell functions: In Phosphodiesterase Inhibitors. ed. Schult, C., Dent, G. & Rabe, K.F. pp. 115-119. London: Academic Press.
14. DENT, G., GIEMBYCZ, MA., EVANS, P.E., RABE, K.F. & BARNES, P.J. (1994). Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther., 271, 1167-1174.
15. 2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line. Biochem. J., 243, 533-539.
16. ESSAYAN, D.M., HUANG, S.-K., UNDEM, B.J., KAGEY-SOBOTKA, A. & LICHTENSTEIN, L.M. (1994). Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol., 153, 3408-3416.
17. FISCHER, W., SCHUDT, C. & WENDEL, A. (1993). Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochem. Pharmacol., 45, 2399-2404.
18. FREUDENBERG, M.A., KEPPLER, D. & GALANOS, C. (1986). Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect. Immun., 165, 657-895.
19. GANTNER, F., KÜSTERS, S., WENDEL, A., SCHUDT, C., HATZELMANN, A. & TIEGS, G. (1997). Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther., 280, 53-60.
20. GANTNER, F., LEIST, M., JILG, S., GERMANN, P.G., FREUDENBERG, M.A. & TIEGS, G. (1995a). Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T cell-dependent liver injury in mice. Gastroenterology, 109, 166-176.
21. GANTNER, F., LEIST, M., KÜSTERS, S., VOGT, K., VOLK, H.-D. & TIEGS, G. (1996). T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp. Cell Res., 229, 137-146.
22. GANTNER, F., LEIST, M., LOHSE, A.W., GERMANN, P.G. & TIEGS, G. (1995b). Concanavalin A-induced and T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology, 21, 190-198.
23. GANTNER, F., SCHUDT, C., WENDEL, A. & HATZELMANN, A. (1995c). Synergistic inhibition of human T cell proliferation by PDE III and PDE IV inhibitors. Inflamm. Res., 44, S263.
24. GENAIN, C.P., ROBERTS, T., DAVIS, R.L., NGUYEN, M.-H., UCCELLI, A., FAULDS, D., LI, Y., HEDGPETH, J. & HAUSER, S.L. (1995). Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U.S.A., 92, 3601-3605.
25. GESSANI, S., TESTA, U., VARANO, B., DI MARZIO, P., BORGHI, P., CONTI, L., BARBERI, T., TRITARELLI, E., MARTUCCI, R., SERIPA, D., PESCHLE, C. & BELARDELLI, F. (1993). Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages. Role of LPS receptors. J. Immunol., 151, 3758-3766.
26. 8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol., 118, 1945-1958.
27. GOLDBEG, A.F. & BARKA, T. (1962). Acid phosphatase activity in human blood cells. Nature, 189, 297-301.
28. GOSSET, P., TSICOPOULOS, A., WALLAERT, B., VANNIMENUS, C., JOSEPH, M., TONNEL, A.B. & CAPRON, A. (1991). Increased secretion of tumour necrosis factor-α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic response. J. Allergy Clin. Immunol., 88, 561-571.
29. HATZELMANN, A., ENGELSTÄTTER, R., MORLEY, J. & MAZZONI, L. (1996). Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors. In Phosphodiesterase Inhibitors. ed. Schudt, C., Dent, G. & Rabe, K.F. pp. 147-160. London: Academic Press.
30. HATZELMANN, A., TENOR, H. & SCHUDT, C. (1995). Differential effects of non-selective and selective phosphodiesterase inhibitors on the inhibition of eosinophil function. Br. J. Pharmacol., 114, 821-831.
31. HOOGSTEDEN, H.C., VAN HAL, P.T., WIJKHUIJS, J.M. & HILVERING, C. (1993). Differences in expression of monocyte/macrophage surface antigens in peripheral blood and bronchoalveolar lavage cells in interstitial lung diseases. Lung, 171, 149-160.
32. HURWITZ, R.L., HIRSCH, K.M., CLARK, D.J., HOLCOMBE, V.N. & HURWITZ, M.Y. (1990). Induction of a calcium, calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. J. Biol. Chem., 265, 8901-8907.
33. ISHIKAWA, Y., MUKAIDA, N., KUNO, K., RICE, N., OKAMOTO, S.-I. & MATSUSHIMA, K. (1995). Establishment of lipopolysaccharide-dependent nuclear factor κB activation in cell-free system. J. Biol. Chem., 270, 4158-4164.
34. JIANG, X., LI, J., PASKIND, M. & EPSTEIN, P.M. (1996). Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc. Natl. Acad. Sci. U.S.A., 93, 11236-11241.
35. JILG, S., BARSIG, J., LEIST, M., KÜSTERS, S., VOLK, H.-D. & WENDEL, A. (1996). Enhanced release of interleukin-10 and soluble tumor necrosis factor receptor as novel principles of methylxanthine action in murine models of endotoxic shock. J. Pharmacol. Exp. Ther., 278, 421-423.
36. JONES, A.L. & SELBY, P. (1989). Tumor necrosis factor: clinical relevance. Cancer Survey, 8, 817-836.
37. 2 inhibits TNF-α release via a mechanism involving IL-10. J. Immunol., 154, 3383-3390.
38. KAMBAYASHI, T., JACOB, C.O., ZHOU, D., MAZUREK, N., FONG, M. & STRASSMANN, G. (1995b). Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol., 155, 4909-4916.
39. KAPLAN, G. & GAUDERNACK, G. (1982). In vitro differentiation of human monocytes. Differences in monocyte phenotype induced by cultivation on glass or on collagen. J. Exp. Med., 156, 1101-1118.
40. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukoc. Biol., 59, 208-218.
41. 2. Biochem. Biophys. Res. Commun., 137, 404-410.
42. LEIST, M., AUER-BARTH, S. & WENDELL, A. (1996). Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines. J. Pharmacol. Exp. Ther., 276, 968-976.
43. LEIST, M., GANTNER, F., BOHLINGER, I., GERMANN, P.G., TIEGS, G. & WENDEL, A. (1994). Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest. J. Immunol., 153, 1778-1787.
44. LEIST, M., GANTNER, F., JILG, S. & WENDEL, A. (1995a). Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol., 154, 1307-1316.
45. LEIST, M., GANTNER, F., BOHLINGER, I., GERMANN, P.G., TIEGS, G. & WENDEL, A. (1995b). Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol., 146, 1220-1236.
46. LEPE-ZUNIGA, J.L. & KLOSTERGAARD, J. (1990). Tolerance to endotoxin in vitro: independent regulation of interleukin-1, tumor necrosis factor and interferon-alpha production during in vitro differentiation of human monocytes. Lymphokine Res., 9, 309-315.
47. LOUGHNEY, K. & FERGUSON, K. (1996). Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. In Phosphodiesterase Inhibitors. ed. Schudt, C., Dent, G. & Rabe, K.F. pp. 1-19. London: Academic Press.
48. MOLNAR-KIMBER, K., YONNO, L., HEASLIP, R. & WEICHMAN, B. (1993). Modulation of TNF-α and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions, 39, C77-C79.
49. MYATT, N., COGHILL, G., MORRISON, K., JONES, D. & CREE, I.A. (1994). Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J. Clin. Pathol., 47, 423-426.
50. NASH, J.R., MCLOUGHLIN, P.J., HOYLE, C. & ROBERTS, D. (1991). Immunolocalization of tumour necrosis factor alpha in lung tissue from patients dying with adult respiratory distress syndrome. Histopathology, 19, 395-402.
51. NEWELL, C.L., DEISSEROTH, A.B. & LOPEZ-BERESTEIN, G. (1994). Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNFα gene. J. Leukoc. Biol., 56, 27-35.
52. PEREZ-ARELLANO, J.L., LOSA-GARCIA, J.E., ORFAO-MATOS, A., GONZALEZ, M., DE LA CRUZ, J.L., JIMENEZ, A. & DE CASTRO, S. (1993). Comparison of two techniques (flow cytometry and alkaline immunophosphatase) in the evaluation of alveolar macrophage immunophenotype. Diagn. Cytopathol., 9, 259-265.
53. PETERS, J.H., GIESELER, R., THIELE, B. & STEINBACH, F. (1996). Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today, 17, 273-278.
54. PLATZER, C., MEISEL, C., VOGT, K., PLATZER, M. & VOLK, H.-D. (1995). Upregulation of monocytic IL-10 by TNF-alpha and cAMP elevating drugs. Int. Immunol., 7, 517-523.
55. PRABHAKAR, U., LIPSHUTZ, D., BARTUS, J.O., SLIVJAK, M.J., SMITH, E.F., LEE, J.C. & ESSER, K.M. (1994). Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol., 16, 805-816.
56. 2 receptors on rat Kupffer cells. Hepatology, 19, 1445-1452.
57. 2 and cyclic nucleotides. J. Immunol., 141, 2388-2393.
58. RENZETTI, L.M., PACIOREK, P.M., TANNU, S.A., RINALDI, N.C., TOCKER, J.E., WASSERMAN, M.A. & GATER, P.R. (1996). Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J. Pharmacol. Exp. Ther., 278, 847-853.
59. ROBICSEK, S.A., BLANCHARD, D.K., DJEU, J.Y., KRZANOWSKI, J.J., SZENTIVANYI, A. & POLSON, J.B. (1991). Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol., 42, 869-877.
60. ROBICSEK, S.A., KRZANOWSKI, J.J., SZENTIVANYI, A. & POLSON, J.B. (1989). High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes. Biochem. Biophys. Res. Commun., 163, 554-560.
61. SATRIANO, J. & SCHLONDORFF, D. (1994). Activation and attenuation of transcription factor NF-κB in mouse glomerular mesenagial cells in response to tumor necrosis factor-α, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate: Evidence for involvement of oxygen species. J. Clin. Invest., 94, 1629-1636.
62. SCHADE, U.F. & SCHUDT, C. (1993). The specific type III and type IV phosphodiesterase inhibitor zardaverine suppressed tumor necrosis factor by macrophages. Eur. J. Pharmacol., 230, 9-14.
63. H2-type T cell clone D10.G4.1. Immunopharmacology, 30, 191-198.
64. SCHUDT, C., TENOR, H. & HATZELMANN, A. (1995). PDE isoenzymes as targets for anti-asthmatic drugs. Eur. Res. J., 8, 1179-1183.
65. SCHUDT, C., TENOR, H., WENDEL, A., ELTZE, M., MAGNUSSEN, H. & RABE, K.F. (1993a). Influence of the PDE III/IV inhibitor B9004-070 in contraction and PDE activities in airway and vascular smooth muscle. Am. Rev. Respir. Dis., 147, A183.
66. SCHUDT, C., TENOR, H., WENDEL, A., RABE, K., LOOS, U., SZAMEL, M. & RESCH, K. (1993b). Effect of selective phosphodiesterase (PDE) inhibitors on activation of human macrophages and lymphocytes. Eur. Res. J., 6(Suppl. 17), 367S.
67. i. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 682-690.
68. SELDON, P.M., BARNES, P.J., MEJA, K. & GIEMBYCZ, M.A. (1995). Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol. Pharmacol., 48, 747-757.
69. SEMMLER, J., GEBERT, U., EISENHUT, T., MOELLER, T., SCHÖN-HARTING, M.M., ALLÉRA, A. & ENDRES, S. (1993a). Xanthine derivatives: Comparison between suppression of tumor necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology, 78, 520-525.
70. SEMMLER, J., WACHTEL, H. & ENDRES, S. (1993b). The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol., 15, 409-413.
71. SEVERN, A., RAPSON, N.T., HUNTER, C.A. & LIEW, F.Y. (1992). Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J. Immunol., 148, 3441-3445.
72. SHAKOV, A.N., COLLART, M.A., VASSALLI, P., NEDOSPASOV, S.A. & JONGENEEL, C.V. (1990). κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor-α gene in primary macrophages. J. Exp. Med., 171, 35-47.
73. SINHA, B., SEMMLER, J., EISENHUT, T., EIGLER, A. & ENDRES, S. (1995). Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol., 25, 147-153.
74. SOMMER, N., LÖSCHMANN, P.-A., NORTHOFF, G.H., WELLER, M., STEINBRECHER, A., STEINBACH, J.P., LICHTENFELS, R., MEYERMANN, R., REITHMÜLLER, A., FONTANA, A., DICHGANS, J. & MARTIN, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med., 1, 244-248.
75. SONNE, O., PEDERSEN, K., KUDAHL, K. & FISKER, S. (1991). A rapid microtitration plate assay for non-specific esterase. Scand. J. Immunol., 33, 231-235.
76. SOUNESS, J.E., GRIFFIN, M., MASLEN, C., EBSWORTH, K., SCOTT, L.C., POLLOCK, K., PALFREYMAN, M.N. & KARLSSON, J.-A. (1996). Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol., 118, 649-658.
77. SOUNESS, J.E., MASLEN, C., WEBBER, S., FOSTER, M., RAEBURN, D., PALFREYMAN, M.N., ASTHON, M.J. & KARLSSON, J.-A. (1995). Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol., 115, 39-46.
78. SPRIGGS, D.R., DEUTSCH, S. & KUFE, D.W. (1991). Genomic structure, induction and production of TNF-α. In The Cytokine Handbook. ed. Thompson, A. W. pp. 1-34. London: Academic Press.
79. STRIETER, R.M., KUNKEL, S.L. & BONE, R.C. (1993). Role of tumor necrosis factor-α in disease states and inflammation. Crit. Care Med., 21, S447-S468.
80. SUN, T. (1985). Atlas of Cytochemistry and Immunochemistry of Hematologic Neoplasms. pp. 24-38. Chicago: American Society of Clinical Pathologist Press.
81. TAFFET, S.M., SINGHEL, K.J., OVERHOLTZER, J.F. & SHURTLEFF, S.A. (1989). Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell. Immunol., 120, 291-300.
82. TENOR, H., HATZELMANN, A., KUPFERSCHMIDT, R., STANCIU, L., DJUKANOVIC, R., SCHUDT, C., WENDEL, A., CHURCH, M.K. & SHUTE, J.S. (1995a). Cyclic phosphodiesterase activities in human alveolar macrophages. Clin. Exp. Allergy, 25, 625-633.
83. + T lymphocytes. Clin. Exp. Allergy, 25, 616-624.
84. TESTA, U., PETRINI, M., QZÙARANTA, M.T., PELOSI-TESTA, E., MASTROBERANDINO, G., CAMAGNA, A., BOCCOLI, G., SARGIACOMO, M., ISACCHI, G., COZZI, A., AROSIO, P. & PESCHLE, C. (1989). Iron upmodulates the expression of transferrin receptors during monocyte-macrophage maturation. J. Biol. Chem., 264, 13181-13187.
85. THOMPSON, W.J. & APPLEMAN, M.M. (1979). Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cycl. Nucl. Res., 10, 69-92.
86. TIEGS, G., WOLTER, M. & WENDEL, A. (1989). Tumor necrosis factor is a terminal mediator in D-galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol., 38, 627-632.
87. TRACEY, K.J. & CERAMI, A. (1993). Tumor necrosis factor: an updated review of its biology. Crit. Care. Med., 21, S415-S423.
88. VECCHIARELLI, A., SIRACUSA, A., CENCI, E., PULITI, M. & ABBRITTI, G. (1992). Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma. Clin. Exp. Allergy, 22, 365-370.
89. VERGHESE, M.W., MCCONNELL, R.T., LENHARD, J.M., HAMACHER, L. & JIN, S.-L.C. (1995). Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol., 47, 1164-1171.
90. WINDSOR, A.C., MÜLLEN, P.G., WALSH, C.J., FISHER, B.J., BLOCHER, C.R., JESMOK, G., FOWLER, A.A. & SUGARMAN, H.J. (1994). Delayed tumor necrosis factor alpha blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis. Arch. Surg., 129, 80-89.
91. YING, S., ROBINSON, D.S., VARNEY, V., MENG, Q., TSICOPOULOS, A., MOQBEL, R., DURHAM, S.R., KAY, A.B. & HAMID, Q. (1991). TNF-alpha mRNA expression in allergic inflammation. Clin. Exp. Allergy, 21, 745-750.
92. + dendritic cells. Proc. Natl. Acad. Sci. U.S.A., 93, 2588-2592.